Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics is poised for success with the recent launch of Zelsuvmi in the molluscum market, as the first approved at-home treatment option for this common pediatric skin infection. KOL feedback and early script trends suggest strong demand for Zelsuvmi, and we expect continued prescriber adoption and improved access to drive sales growth, reaching $275M at peak. With a sub-$250M market cap and a strong launch trajectory, Pelthos is an undervalued commercial execution story with potential for a significant valuation re-rating.

Bears say

Pelthos Therapeutics is a commercial-stage biopharmaceutical company with an expanding pipeline and FDA-approved assets, including Zelsuvmi, for the treatment of molluscum contagiosum. While Zelsuvmi's launch has been successful, it faces a paradox of a large market with low treatment penetration, and its impact on the company's overall financials will not be significant until 2026. The company's long IP runway provides room for potential growth, but its current financials may not justify its stock's high valuation.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.